What development phase is Alfadione in?

Alfadione is FDA-approved (marketed).

What is the generic name of Alfadione?

ALFAXALONE is the generic (nonproprietary) name of Alfadione.

Last reviewed 2026-04-20 · How we verify

Alfadione (ALFAXALONE)

FDA-approved active Small molecule Quality 15/100

Alfaxalone is a marketed anesthetic agent that binds to GABA A receptors to produce a calming effect and induce anesthesia, currently holding a niche position in the anesthetic market. Its key strength lies in its unique mechanism of action, which differentiates it from off-patent competitors such as ketamine, etomidate, and propofol. The primary risk is the potential loss of exclusivity in 2028 when the key composition patent expires, exposing Alfaxalone to generic competition.

At a glance

Generic name	ALFAXALONE
Drug class	alfaxalone
Target	Sodium- and chloride-dependent GABA transporter 1, GABA A receptor alpha-2/beta-2/gamma-2, GABA-A receptor alpha-1/beta-2/gamma-2
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Alfadione CI brief — competitive landscape report
Alfadione updates RSS · CI watch RSS